Eloxatin

Bone Neoplasms

Peter MacCallum Cancer Centre, AustraliaPhase 1Dormant

CC

47/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 32/ 100
Competitive Position: 95/ 100

Competitive context

0 Active assets in the Bone Neoplasms cohort.

Asset / Sponsor	Phase	Rating
Zoledronate AstraZeneca	Phase 4	BB
Pregabalin Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Phase 4	BB
azd0530 AstraZeneca	Phase 2	B
Calcium folinate pentahydrate Peter MacCallum Cancer Centre, Australia	Phase 1	CC
CTAP-101 OPKO Health, Inc.	Phase 1	CC

View all 9 →

Same molecule, other indications

Eloxatin is also rated in:

exocrine pancreatic carcinomaDormant

BBB

Indicative ·

78 / 100

colon adenocarcinomaDormant

BBB

Indicative ·

77 / 100

colorectal neoplasmDormant

BBB

Indicative ·

74 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.